Modern VaccinesAdjuvants Formulation

15-17 May 2013, CHUV, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 16th May

SESSION 5:
MODELS FOR ADJUVANT ASSESSMENT

Moderator: To be confirmed

09.00-09.30
‘Novel models to evaluate modern vaccine adjuvants’
Alex Mann and Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)

09.30-10.00
In vitro modeling of age-specific human immunity to inform development of adjuvanted vaccines’
Ofer Levy (Harvard Medical School, Boston, Massachusetts, USA)

10.00-10.30
‘New lymphatic targeting strategies for therapeutic vaccination’
Melody A. Swartz, Susan N. Thomas, Laura Jeanbart, Marie Ballester, Alexandre de Titta, Efthymia Vokali and Sachiko Hirosue (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)

10.30-11.00
Coffee Break & Posters

SESSION 6:
VACCINE & ADJUVANT FORMULATION & PRODUCTION

Moderator: Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)

11.00-11.30
‘Characterization of vaccine formulations with adjuvants’
Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)

11.30-12.00
‘Engineering a CD8+ T-cell-inducing vaccine adjuvant through rational formulation design’
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

12.00-12.20
‘Progress to rabies vaccine production in Nepal’
Ganesh Raj Pant (Rabies Vaccine Production Laboratory, Kathmandu, Nepal)

12.20-13.30
Lunch Break & Posters

SESSION 7:
VACCINES

Moderator: Heather G. Davis (Pfizer Vaccine Research, Ottawa, Canada)

13.30-14.00
‘NIC7 anti-nicotine vaccine for smoking cessation’
Heather G. Davis (Pfizer Vaccine Research, Ottawa, Canada)

14.00-14.30
‘Evaluation of a virosomal Respiratory Syncytial Virus vaccine adjuvanted with monophosphoryl lipid A in cotton rats’
Toon Stegmann, Tobias Kamphuis, Aalzen de Haan, Muhammed Shafique, Tjarko Meijerhof and Jan Wilschut (Mymetics BV, Leiden, The Netherlands)

14.30-15.00
‘Enteric fever and pneumococcal protein capsular matrix vaccines’
Kevin Killeen (Matrivax Inc., Boston, Massachusetts, USA)

15.00-15.30
‘Manufacture of an intranasal viral flu vaccine’
Matthew Downham (Medimmune, Liverpool, UK)

15.30-15.50
‘Development of the intranasal RSV F subunit vaccine SynGEM®’
Natalija Van Braeckel-Budimir, Kees Leenhouts, Bert Jan Haijema, Ivy Widjaja, Alan Rigter, Xander de Haan and Peter Rottier (Mucosis BV, Groningen, The Netherlands)

15.50-16.05
Tea Break & Posters

SESSION 8:
ADJUVANT AND VACCINE DELIVERY SYSTEMS

Moderator: Matthew Downham (Medimmune, Liverpool, UK)

16.10-16.40
‘Optimizing delivery of novel immune potentiators’
Michele Pallaora (Novartis Vaccines, Holly Springs, North Carolina, USA)

16.40-17.00
‘Delivery systems for peptide vaccines’
Istvan Toth (The University of Queensland, Brisbane, Queensland, Australia)

17.00-17.20
‘Self-replicating RNA vaccine delivery to dendritic cells by chitosan-nanogel delivery’
Panagiota Milona, Isabelle Bassi, Rolf Suter, Nicolas Ruggli and Kenneth C. McCullough (Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

17.20-17.40
‘Induction of potent CD8+ T cell responses through the delivery of vaccines to skin antigen-presenting cells (APCs) using a microprotection array (Nanopatch™)’
Germain J.P. Fernando, Hwee-Ing Ng and Mark A.F. Kendall (The University of Queensland, Brisbane, Queensland, Australia)

17.40-18.00
‘A therapeutic virosome-based vaccine against recurrent C. albicans vaginitis: Phase I data for intramuscular and intravaginal route of immunization’
M. Mueller, M. Kaiser, A. Amacker and C. Moser (Pevion Biotech AG, Ittigen/Bern, Switzerland)

18.00-18.20
‘Clinical validation of a novel self-adjuvanting peptide-based pan influenza A T-cell vaccine’
James Francis (Immune Targeting Systems Ltd, London, UK)

Free Evening for Delegates

 

MVAF 2013 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2013 Sponsors

  • Vaccine Formulation Laboratory
  • Izon
  • Novartis Vaccines
  • IDRI
  • Mucosis
  • Immune Solutions
  • Retroscreen Virology
  • European Adjuvant Advisory Committee
  • Seppic
  • Aldevron
  • Inovio
  • Dynavax
  • Wittycell
  • Immune Design
  • Pfizer
  • Vironova
  • CSL
  • Intercell
  • Univac
  • Viscogel
  • Brenntag
  • Vedantra Pharmaceuticals
  • DNA Vaccine
  • Pharvat
  • Sanofi Pasteur

MVAF 2013 Downloads

MVAF 2013 Leaflet

MVAF 2013 Mailing List

Name
E-mail Address
What is 1+4-2?